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EVOLVING ISSUES INONCOLOGY
Global Oncology
In proposing a common global health definition a de-
cade ago, the Consortium of Universities for Global
Health,which includesmore than 170academic institu-
tions and partners worldwide, emphasizedmoving be-
yond a vague, “fashionable” discipline toward a scien-
tifically rigorous specialty that engenders international
cooperation among academic health centers, govern-
ment agencies, industry, andnongovernmental organi-
zations to understand and improve health. Intrinsic to
this vision is the idea that similarhealthdisparities affect
vulnerable communities in North American inner cities
and African periurban shantytowns.
Substantial health disparities exist for cancer. In
2018, 59% of new cancer cases and 70% of cancer
deaths occurred in low- andmiddle-income countries.1
The recent emergence of global oncology as an aca-
demic discipline seeks topromote scientific and clinical
advances for cancer worldwide but also may risk rel-
egating these efforts to a small corner of academia in
highly specialized journals andmeetings. Indeed, itmay
be as appropriate to describe incremental gains in can-
cer control in regionswhere resources are relatively un-
constrained as high-income–country oncology. Aside
fromthestrongmoral argument toaddress cancereven
when itoccursoutside theUnitedStates, restrictingcan-
cer care and research to high-income countries un-
equivocallydiminishes theuniverseofdiscoveries in ser-
vice of cancer patients worldwide.
The National Cancer Institute (NCI), many aca-
demic cancer centers, private foundations, and phar-
maceutical companies have demonstrated interest in
global oncology throughmyriadnewprogramsandcol-
laborations in low- and middle-income countries in re-
cent years (Table). These initiatives often combine re-
search, clinical care, andtraining toensuresustainability.
Efforts have capitalized on successes in other disease
areas with a longer history of global engagement, in-
cludinghuman immunodeficiencyvirus (HIV) andother
infectiousdiseases, forwhichmajor global health initia-
tives have catalyzed rapid gains in life expectancy and
promotedeconomicandpolitical stability.2Although in-
ternational development agencies have not historically
prioritized cancer, this is now changing, particularly for
cervical cancer and childhood cancers, for which the
World Health Organization launched major new initia-
tives in 2018.
With this accumulating interest and investment,
transformational opportunities lie ahead. Low- and
middle-income countries provide unique translational
research prospects in carcinogenesis and therapeutics,
especially for infection-associated malignancies. As an
example, recent integrative genomic and transcrip-
tomic characterization of children with Burkitt lym-
phoma in Africa and North America demonstrated
molecular features largely driven by the presence or
absence of Epstein-Barr virus (EBV) rather than geo-
graphic location.3 Analogous efforts are ongoing for
other cancers with proven or postulated infectious eti-
ologies (eg, Kaposi sarcoma and conjunctival squamous
cell carcinoma), which importantly must be undertaken
within cohorts or trials that ensure participants have
access to appropriate standards of care.
Low- and middle-income countries can also be
accelerators for developing new technologies for can-
cer screening, diagnosis, prognosis, and treatment
monitoring such as visual inspectionwith acetic acid for
cervical cancer screening. Efforts to improve on visual
inspection have added automated visual evaluation of
cervical images taken by a fixed-focus camera using a
deep learning algorithm, an approach that outper-
formed conventional cytology at identifying precancer
or cancer,4 and might help address the limited scalabil-
ity of cervical cytology in countries of all resource lev-
els. Innovative data systems, like OpenMRS, have also
been developed in low- and middle-income countries
to monitor patients with HIV and tuberculosis during
treatment, and provide an open-source, cost-free plat-
form now deployed in more than 40 countries for big
data science, with ongoing adaptation for new disease
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Table. Representative Examples of Recent Global Oncology
Initiatives Involving US Institutions
Institution Type Examples
National Cancer
Institute
Dedicated Center for Global Health
established in 2011
Expansion of AIDS Malignancy Consortium
cooperative clinical trials group to
include clinical trial sites in Africa
and Latin America
Intramural collaborations with low-
and middle-income countries initiated
by individual investigators
Cancer centers Indiana University-AMPATH [Academic
Model Providing Access to Healthcare]
collaboration
Fred Hutchinson Cancer Research
Center-Uganda Cancer Institute
collaboration
University of North Carolina-Malawi
Ministry of Health collaboration
Texas Children’s Hospital Global
Hematology Oncology Programs
of Excellence
Professional
societies
American Society of Clinical Oncology
international programs
American Society of Hematology global
initiatives
Industry Novartis-Max Foundation Glivec (imatinib)
International Patient Assistance Program
Pfizer and Cipla partnering with American
Cancer Society and Clinton Health Access
Initiative to increase access to essential
chemotherapy agents in Africa
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areas like oncology.5 Similarly, a novel mobile health system is sup-
porting a 5-country study involving 2000 women with breast can-
cer in Africa to better understand cultural, patient, and health sys-
tem drivers of poor outcomes.6 These developments provide a
foundation for increased application of artificial intelligence and
mobile health solutions to inform diagnostic and therapeutic
decision-making.
In addition to improvements in overall cancer care infrastruc-
ture, clinical trials can provide access to treatments otherwise un-
available to patients in low- andmiddle-income countries, while si-
multaneously yieldinggeneralizableknowledge. Forexample, a trial
amongwomenwithmetastatic ERBB2 (HER2)–positive breast can-
cer across 16 countries, primarily low- and middle-income coun-
tries,demonstratedequivalent24-weekresponsesforatrastuzumab
biosimilar comparedwith trastuzumab.7These findingsprovideevi-
dence toallowpolicymakersandpharmaceutical companies towork
together to expand access and lower costs for this essential cancer
medicine among eligible patients worldwide, analogous to previ-
ous efforts for HIV treatment. An ongoing randomized trial involv-
ing 25000women in Costa Rica is testing whether 1 vaccine dose
is equivalent to 2 doses for preventing persistently high-risk hu-
man papillomavirus (HPV) infection,8 which again would have im-
portant cost and coverage implications even for the United States.
Recent data for pomalidomide among patients with Kaposi sar-
coma supported an international validation study in Africa spon-
sored by the AIDSMalignancy Consortium,9 the first NCI coopera-
tive clinical trials groupconductingmulticenter therapeutic studies
for cancer in the region. If successful, this could provide key evi-
dence with global benefit for an oral, well-tolerated, noncytotoxic
option for this common HIV-associated cancer.
However, even the most robust new technologies and thera-
pies will not favorably affect public health if not accompanied by
strengthened human capacity, informed policies, and behavior
change. Addressing a limited oncologyworkforce and research ca-
pacity in low- andmiddle-income countries is critical to future sus-
tainability and self-sufficiency beyond clinical trials. Unprec-
edented,bidirectional trainingand teamscienceopportunitiesnow
exist, given the increasingnumberofbasic, clinical, andpublichealth
investigators in theUnitedStatesendorsingcareer interests inglobal
oncology. By supporting future oncology leaders from both high-
income countries and low- andmiddle-income countries, opportu-
nities are emerging to build durable networks and teams that span
the globe. Examples already exist frommany high-income country
cancer centers engaged in such partnershipwith academic or clini-
cal institutions,orministriesofhealth in low-incomecountries.These
bilateral relationships are most successful when academic mis-
sions are aligned, leadership is shared, and institutional commit-
ments are long-term. Ideally, these relationships include embed-
ding fromhigh-incomecountriespersonnel to low-incomecountries
andprovidingextended trainingopportunities forpersonnel in low-
andmiddle-incomecountries in thehigh-incomecountries.As these
nascentglobal oncology teamsmature, it seems inevitable that can-
cer discoverywill become increasingly geographically agnostic, but
itwill alsobeessential toensure thatdiscoveries areequitably trans-
lated into tangiblebenefits for individual patients andpublic health.
TheAmericanSocietyofClinicalOncologyhasongoing initiatives to
facilitate exchange between oncologists in low- and middle-
income countries and the United States and to support oncology
workforce development in low- andmiddle-income countries. Be-
cause the key factors underlying global cancer disparities like high
treatment costs and limited access are important issues in all coun-
tries,globaloncologistsworkingcollaborativelywill likelybebestpo-
sitioned to help address these barriers.
To confine cancer care and research to resource-rich countries
is to forgo transformative scientific and educational opportunities.
NorthAmerican cancer centers are international leaders in patient-
centered innovation, and their catchment areas need not be nar-
rowly defined. Maximizing service to local geography and striving
forglobal impact arenot irreconcilableobjectives. Low-andmiddle-
income countries can be innovation hubs, where challenging envi-
ronments inspire and test innovative solutions for cancer that can
be applied worldwide. Embracing this philosophy will allow global
oncology ultimately to be replaced by a perhapsmore appropriate
universal oncologydiscipline,which is not just apassing fashionbut
instead could represent a powerful driver of forward progress for
cancer patients around the world.
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